Please use this identifier to cite or link to this item: https://doi.org/10.1038/eye.2012.72
DC FieldValue
dc.titleRetinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period
dc.contributor.authorWickremasinghe, S.S.
dc.contributor.authorXie, J.
dc.contributor.authorGuymer, R.H.
dc.contributor.authorWong, T.Y.
dc.contributor.authorKawasaki, R.
dc.contributor.authorQureshi, S.
dc.date.accessioned2014-11-26T07:47:54Z
dc.date.available2014-11-26T07:47:54Z
dc.date.issued2012-07
dc.identifier.citationWickremasinghe, S.S., Xie, J., Guymer, R.H., Wong, T.Y., Kawasaki, R., Qureshi, S. (2012-07). Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. Eye (Basingstoke) 26 (7) : 958-966. ScholarBank@NUS Repository. https://doi.org/10.1038/eye.2012.72
dc.identifier.issn0950222X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/109608
dc.description.abstractPurpose: To assess retinal vascular calibre changes in eyes with neovascular age-related macular degeneration (AMD), treated with intravitreal anti-vascular endothelial growth factor agents, over a 1-year period and compare any such changes to untreated fellow eyes. Methods: Treatment naïve patients with neovascular AMD received three consecutive intravitreal injections of ranibizumab, followed by a pro re nata dosing regimen up to 1 year, with the aim of maintaining a 'fluid-free' macula. Retinal arteriolar and venular calibre was measured from digital fundus photographs at baseline and at three monthly intervals to 1 year, and summarised as central retinal artery equivalent (CRAE) and central retinal venular equivalent (CRVE), respectively. Results: A total of 53 injected eyes and 41 fellow, non-injected eyes were analysed. At baseline, there were no differences in retinal vascular calibre between injected and non-injected eyes (mean CRAE (SD) 144.93 (14.07) vs 145.74 (13.10) μm, P=0.80 and mean CRVE (SD) 216.23 (25.93) vs 219.91 (22.82) μm, P=0.53). Over a 12-month period, retinal venular calibre dilatation occurred in injected eyes (mean CRVE change +5.71 (14.71) μm, P=0.007), with no change in retinal arterioles, +0.69 (14.71) μm, P=0.68. In non-injected eyes, arteriolar narrowing occurred as a whole, mean CRAE change -4.20 (7.00) μm, P=0.001, over 12 months, with a trend for narrowing in venules, -2.16 (11.56) μm, P=0.28. In injected eyes, after controlling for covariates, the changes in CRVE over 12 months mirrored improvements in macular thickness, -0.06 (-0.005, -0.11) μm, P=0.04, and visual acuity, +9.66 (-0.30, +19.32) μm, P=0.06. Conclusion: Intravitreal ranibizumab significantly dilated retinal venules after a 1-year period. © 2012 Macmillan Publishers Limited All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/eye.2012.72
dc.sourceScopus
dc.subjectAMD
dc.subjectanti-VEGF
dc.subjectretinal vasculature
dc.typeArticle
dc.contributor.departmentOPHTHALMOLOGY
dc.description.doi10.1038/eye.2012.72
dc.description.sourcetitleEye (Basingstoke)
dc.description.volume26
dc.description.issue7
dc.description.page958-966
dc.description.codenEYEEE
dc.identifier.isiut000306360800009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

8
checked on Feb 2, 2023

WEB OF SCIENCETM
Citations

8
checked on Feb 2, 2023

Page view(s)

171
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.